Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

NCT03383978 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
42
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Johann Wolfgang Goethe University Hospital

Collaborators